260 related articles for article (PubMed ID: 11584892)
21. [Cytofluorometric analysis of chosen markers of apoptosis CD95/CD95L (Fas/FasL) in thyroid tissues from young patients with Graves' disease and Hashimoto's thyroiditis].
Bossowski A; Stasiak-Barmuta A; Czarnocka B; Urban M; Łyczkowska A; Niedziela M; Bardadin K; Czerwińska J; Dadan J; Baltaziak M
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(2):83-90. PubMed ID: 16813711
[TBL] [Abstract][Full Text] [Related]
22. Expression of Fas/APO-1 during the progression of astrocytomas.
Tachibana O; Nakazawa H; Lampe J; Watanabe K; Kleihues P; Ohgaki H
Cancer Res; 1995 Dec; 55(23):5528-30. PubMed ID: 7585627
[TBL] [Abstract][Full Text] [Related]
23. Induction of Fas expression and augmentation of Fas/Fas ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells.
Sun SY; Yue P; Hong WK; Lotan R
Cancer Res; 2000 Nov; 60(22):6537-43. PubMed ID: 11103825
[TBL] [Abstract][Full Text] [Related]
24. The role of Fas and FasL as mediators of anticancer chemotherapy.
Poulaki V; Mitsiades CS; Mitsiades N
Drug Resist Updat; 2001 Aug; 4(4):233-42. PubMed ID: 11991678
[TBL] [Abstract][Full Text] [Related]
25. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.
Müller M; Strand S; Hug H; Heinemann EM; Walczak H; Hofmann WJ; Stremmel W; Krammer PH; Galle PR
J Clin Invest; 1997 Feb; 99(3):403-13. PubMed ID: 9022073
[TBL] [Abstract][Full Text] [Related]
26. Expression of Fas (CD95) and FasL (CD95L) in human airway epithelium.
Hamann KJ; Dorscheid DR; Ko FD; Conforti AE; Sperling AI; Rabe KF; White SR
Am J Respir Cell Mol Biol; 1998 Oct; 19(4):537-42. PubMed ID: 9761749
[TBL] [Abstract][Full Text] [Related]
27. CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants.
Eberle J; Fecker LF; Hossini AM; Wieder T; Daniel PT; Orfanos CE; Geilen CC
Oncogene; 2003 Dec; 22(57):9131-41. PubMed ID: 14668794
[TBL] [Abstract][Full Text] [Related]
28. Production and pro-apoptotic activity of soluble CD95 ligand in pancreatic carcinoma.
Bellone G; Smirne C; Carbone A; Mareschi K; Dughera L; Farina EC; Alabiso O; Valente G; Emanuelli G; Rodeck U
Clin Cancer Res; 2000 Jun; 6(6):2448-55. PubMed ID: 10873098
[TBL] [Abstract][Full Text] [Related]
29. DNA damage signals induction of fas ligand in tumor cells.
Mo YY; Beck WT
Mol Pharmacol; 1999 Feb; 55(2):216-22. PubMed ID: 9927611
[TBL] [Abstract][Full Text] [Related]
30. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity.
Mitsiades N; Yu WH; Poulaki V; Tsokos M; Stamenkovic I
Cancer Res; 2001 Jan; 61(2):577-81. PubMed ID: 11212252
[TBL] [Abstract][Full Text] [Related]
31. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines.
Weller M; Frei K; Groscurth P; Krammer PH; Yonekawa Y; Fontana A
J Clin Invest; 1994 Sep; 94(3):954-64. PubMed ID: 7521890
[TBL] [Abstract][Full Text] [Related]
32. Fas (Apo-1, CD95) receptor expression in childhood astrocytomas. Is it a marker of the major apoptotic pathway or a signaling receptor for immune escape of neoplastic cells?
Bodey B; Bodey B; Siegel SE; Kaiser HE
In Vivo; 1999; 13(4):357-73. PubMed ID: 10586378
[TBL] [Abstract][Full Text] [Related]
33. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo.
Rensing-Ehl A; Frei K; Flury R; Matiba B; Mariani SM; Weller M; Aebischer P; Krammer PH; Fontana A
Eur J Immunol; 1995 Aug; 25(8):2253-8. PubMed ID: 7545115
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of Fas-induced apoptosis by Bcl-2.
Kawahara A; Kobayashi T; Nagata S
Oncogene; 1998 Nov; 17(20):2549-54. PubMed ID: 9840917
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of Fas/Fas ligand-mediated apoptotic cell death of lymphocytes in vitro by circulating anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus.
Suzuki N; Ichino M; Mihara S; Kaneko S; Sakane T
Arthritis Rheum; 1998 Feb; 41(2):344-53. PubMed ID: 9485093
[TBL] [Abstract][Full Text] [Related]
36. Cholangiocarcinomas express Fas ligand and disable the Fas receptor.
Que FG; Phan VA; Phan VH; Celli A; Batts K; LaRusso NF; Gores GJ
Hepatology; 1999 Dec; 30(6):1398-404. PubMed ID: 10573518
[TBL] [Abstract][Full Text] [Related]
37. Apoptosis signaling pathways in normal T cells: differential activity of Bcl-2 and IL-1beta-converting enzyme family protease inhibitors on glucocorticoid- and Fas-mediated cytotoxicity.
Moreno MB; Memon SA; Zacharchuk CM
J Immunol; 1996 Nov; 157(9):3845-9. PubMed ID: 8892614
[TBL] [Abstract][Full Text] [Related]
38. CD40 activation-induced, Fas-dependent apoptosis and NF-kappaB/AP-1 signaling in human intrahepatic biliary epithelial cells.
Afford SC; Ahmed-Choudhury J; Randhawa S; Russell C; Youster J; Crosby HA; Eliopoulos A; Hubscher SG; Young LS; Adams DH
FASEB J; 2001 Nov; 15(13):2345-54. PubMed ID: 11689460
[TBL] [Abstract][Full Text] [Related]
39. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand.
von Bernstorff W; Spanjaard RA; Chan AK; Lockhart DC; Sadanaga N; Wood I; Peiper M; Goedegebuure PS; Eberlein TJ
Surgery; 1999 Jan; 125(1):73-84. PubMed ID: 9889801
[TBL] [Abstract][Full Text] [Related]
40. Apoptosis induced in T cells by human neuroblastoma cells: role of Fas ligand.
Shurin GV; Gerein V; Lotze MT; Barksdale EM
Nat Immun; 1998; 16(5-6):263-74. PubMed ID: 11061594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
